Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-61

@Mason14 thanks for your very detailed analysis. Look forward to seeing more details of the trial, whether that's through a future trial design poster for a scientific congress and/or whatever gets posted to a repository such as clinical trials.gov.
There may be a case if you're trying to show a cardioprotective effect to go the other way actually and enrol a higher background CVD risk population IE enriched, after all you need the events to occur to show you can reduce the risk, perhaps it'll be where bisantrene is most effective! The other question here is whether their protocol will limit previous (or concurrent) HER2-directed therapy use.
The 2022 ESC cardio-oncology guidelines are excellent and give a lot of detail in risk stratification, assessment and management of anthracyclin cardiotoxicity. Wonder if RACE has considered these in its development of its protocol. EHJ 2022; 43; 4229-4361